PD-1 signaling and inhibition in AML and MDS.

about

Therapeutic vaccination with 4-1BB co-stimulation eradicates mouse acute myeloid leukemia

P2860

Q57138588-DC4FE4A9-380B-492D-BCBE-53FB03830CB5

P2860

PD-1 signaling and inhibition in AML and MDS.

Item

http://www.wikidata.org/entity/Q39393084

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

PD-1 signaling and inhibition in AML and MDS.

@en

PD-1 signaling and inhibition in AML and MDS.

@nl

type

Item

label

PD-1 signaling and inhibition in AML and MDS.

@en

PD-1 signaling and inhibition in AML and MDS.

@nl

prefLabel

PD-1 signaling and inhibition in AML and MDS.

@en

PD-1 signaling and inhibition in AML and MDS.

@nl

P1476

PD-1 signaling and inhibition in AML and MDS

@en

P2093

Imad Tabbara

http://www.w3.org/2001/XMLSchema#string

Sade A Solola

http://www.w3.org/2001/XMLSchema#string

Samah Nassereddine

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

How we treat lower-risk myelodysplastic syndromes.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Acute myeloid leukemia: epidemiology and etiology.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

Acute myeloid leukemia in the real world: why population-based registries are needed.

P304

1441-1448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3051-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Faysal Haroun

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28643044

http://www.w3.org/2001/XMLSchema#string

PD-1 signaling and inhibition in AML and MDS.

about

P2860

P2860

PD-1 signaling and inhibition in AML and MDS.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698